DeepMed Research

ABBVIE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

A Study to Evaluate Adverse Events and Change in Disease State of Oral Upadacitinib in Adolescent Participants Ages 12 to <18 Years Old Diagnosed With Atopic Dermatitis (AD)

Recruiting

Conditions: Atopic Dermatitis

First Posted Date: 2021-09-01

Last Posted Date: 2024-06-20

Lead Sponsor: AbbVie

Target Recruit Count: 170

Registration Number: NCT05029895

Locations: 🇯🇵
Kobe City Medical Center General Hospital /ID# 250836, Kobe-shi, Hyogo, Japan
🇯🇵
Hosui General Medical Clinic /ID# 241881, Sapporo-shi, Hokkaido, Japan
🇯🇵
Takeoka Dermatology Clinic /ID# 240610, Marugame, Kagawa, Japan

and more 56 locations

Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine

Phase 3

Completed

Conditions: Episodic Migraine

Interventions: Drug: BOTOX
Drug: Placebo

First Posted Date: 2021-08-31

Last Posted Date: 2024-12-06

Lead Sponsor: AbbVie

Target Recruit Count: 775

Registration Number: NCT05028569

Locations: 🇺🇸
Albuquerque Clinical Trials, Inc. /ID# 231101, Albuquerque, New Mexico, United States
🇺🇸
Duplicate_University Of Cincinnati Medical Center /ID# 231739, Cincinnati, Ohio, United States
🇨🇿
Fakultní Nemocnice U Sv. Anny V Brně /ID# 232213, Brno, Brno-mesto, Czechia

and more 130 locations

A Study to Assess Patient-Reported Quality of Life and Effectiveness on Control of Bleeding in Adult Participants With Heavy Menstrual Bleeding Due to Uterine Fibroids Taking Oral Oriahnn Capsules

Terminated

Conditions: Heavy Menstrual Bleeding
Uterine Fibroids

First Posted Date: 2021-08-30

Last Posted Date: 2023-08-14

Lead Sponsor: AbbVie

Target Recruit Count: 23

Registration Number: NCT05026502

Locations: 🇺🇸
IQVIA RDS, Inc., Durham, North Carolina, United States

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or Bevacizumab

Phase 1

Recruiting

Conditions: Non-Small Cell Lung Cancer
Head and Neck Squamous Cell Carcinoma
Micro Satellite Stable Colorectal Cancer
Gastric/Esophageal Cancer
High-Grade Serous Ovarian Cancer
Pancreatic Cancer
Triple Negative Breast Cancer

Interventions: Drug: Azirkitug
Drug: Budigalimab
Drug: Bevacizumab

First Posted Date: 2021-08-13

Last Posted Date: 2025-05-20

Lead Sponsor: AbbVie

Target Recruit Count: 512

Registration Number: NCT05005403

Locations: 🇮🇱
Rambam Health Care Campus /ID# 238333, Haifa, H_efa, Israel
🇮🇱
Hadassah Medical Center-Hebrew University /ID# 252287, Jerusalem, Israel
🇮🇱
Rabin Medical Center /ID# 250497, Petah Tikva, Israel

and more 26 locations

A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence

Phase 3

Completed

Conditions: Platysma Prominence

Interventions: Drug: OnabotulinumtoxinA
Drug: Placebo

First Posted Date: 2021-08-06

Last Posted Date: 2024-08-20

Lead Sponsor: AbbVie

Target Recruit Count: 426

Registration Number: NCT04994535

Locations: 🇺🇸
Westside Aesthetics /ID# 231196, Los Angeles, California, United States
🇺🇸
DeNova Research /ID# 231191, Chicago, Illinois, United States
🇺🇸
Skin and Cancer Associates, LLP /ID# 231189, Miami, Florida, United States

and more 31 locations

A Study to Evaluate an Updated Dexamethasone Intravitreal (Into the Eye) Applicator in Adult Participants With Macular Edema Due to Diseases of the Retina

Phase 3

Completed

Conditions: Macular Edema

Interventions: Device: Updated DEX PS DDS Applicator
Device: Approved DEX PS DDS Applicator
Drug: Dexamethasone

First Posted Date: 2021-07-26

Last Posted Date: 2023-02-28

Lead Sponsor: AbbVie

Target Recruit Count: 54

Registration Number: NCT04976777

Locations: 🇺🇸
North Texas Retina Consultants /ID# 241013, Willow Park, Texas, United States
🇺🇸
Global Research Management /ID# 238944, Glendale, California, United States
🇺🇸
Retina Research Institute of Texas /ID# 231420, Abilene, Texas, United States

and more 4 locations

A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154

Phase 2

Terminated

Conditions: Polymyalgia Rheumatica

Interventions: Drug: ABBV-154
Drug: Placebo
Drug: Glucocorticoid

First Posted Date: 2021-07-22

Last Posted Date: 2024-10-11

Lead Sponsor: AbbVie

Target Recruit Count: 181

Registration Number: NCT04972968

Locations: 🇭🇺
Kistarcsai Flor Ferenc Korhaz /ID# 229676, Kistarcsa, Hungary
🇯🇵
Kuwana city medical center /ID# 231936, Kuwana-shi, Mie, Japan
🇪🇸
Hospital Universitario Marques de Valdecilla /ID# 229297, Santander, Cantabria, Spain

and more 114 locations

A Study To Assess Adverse Events and Change in Disease Activity With Oral Cariprazine When Added to Antidepressant Therapies (ADTs) Compared to Placebo in Adult Participants With Generalized Anxiety Disorder (GAD) Who Have Had an Inadequate Response to ADTs Alone

Phase 2

Withdrawn

Conditions: Generalized Anxiety Disorder

Interventions: Drug: Cariprazine 1.5 mg/day
Drug: Cariprazine 0.75 mg/day
Drug: Cariprazine 3.0 mg/day
Other: Placebo

First Posted Date: 2021-07-16

Last Posted Date: 2022-04-12

Lead Sponsor: AbbVie

Registration Number: NCT04965272

Locations: 🇺🇸
ATP Clinical Research, Inc /ID# 230445, Costa Mesa, California, United States
🇺🇸
FutureSearch Trials of Dallas, LP /ID# 230535, Dallas, Texas, United States
🇺🇸
Anderson Clinical Research /ID# 230440, Redlands, California, United States

and more 33 locations

A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy

Phase 2

Completed

Conditions: Apathy in Dementia

Interventions: Drug: CVL-871 1.0 mg
Drug: CVL-871 3.0 mg
Drug: Placebo

First Posted Date: 2021-07-12

Last Posted Date: 2025-04-02

Lead Sponsor: AbbVie

Target Recruit Count: 41

Registration Number: NCT04958031

Locations: 🇺🇸
Scottsdale, Arizona, Scottsdale, Arizona, United States
🇺🇸
Little Rock, Arkansas, Little Rock, Arkansas, United States
🇺🇸
San Diego, California, San Diego, California, United States

and more 16 locations

A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Moderate to Severe Platysma Prominence

Phase 3

Completed

Conditions: Platysma Prominence

Interventions: Drug: OnabotulinumtoxinA
Drug: Placebo

First Posted Date: 2021-07-02

Last Posted Date: 2024-11-20

Lead Sponsor: AbbVie

Target Recruit Count: 408

Registration Number: NCT04949399

Locations: 🇺🇸
Laser and Skin Surgery Center of Indiana /ID# 229515, Indianapolis, Indiana, United States
🇺🇸
Advanced Research Associates - Glendale /ID# 229256, Glendale, Arizona, United States
🇺🇸
Clinical Testing of Beverly Hills /ID# 229946, Encino, California, United States

and more 27 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy